Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | ADCLEC.SYN1: combinatorial CAR shows preclinical potential for R/R AML

Sascha Haubner • 21 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia ADCLEC.SYN1 CAR-T

Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the rationale for a chimeric antigen receptor (CAR) designed to target both ADGRE2 and CLEC12A in order to enhance anti-leukemic efficacy without increasing toxicity in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). ADGRE2 and CLEC12A are both highly co-expressed in AML, but with low levels of overlapping expression in normal cells. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Sascha Haubner, MD, has received research support from Takeda Pharmaceutical Company Ltd.

More from Sascha Haubner

6:59
ADCLEC.syn1 CAR: ADGRE2-targeting 28z1XX-CAR and a CLEC12A-targeting CCR in humanized AML models
Sascha Haubner • 9 Jun 2023
2:08
Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner • 10 Feb 2023
0:59
Future role of CAR-T in AML
Sascha Haubner • 21 Jun 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals